Trend of β-lactam Resistance in Escherichia coli and Klebsiella pneumoniae Bacteremia and Clinical Characteristics of Cefotaxime-susceptible Extended-spectrum β-lactamase-producing Isolatesopen accessEscherichia coli와 Klebsiella pneumoniae 균혈증의 베타락탐 내성 추세와 세포탁심 감수성 ESBL 생성균주의 임상적 특징
- Authors
- 서현지; 김해인; 박성희; 정혜민; 배성만; 성흥섭; 김미나; 정지원; 김민재; 김성한; 이상오; 최상호; 김양수; 정용필
- Issue Date
- Jun-2023
- Publisher
- 대한의료관련감염관리학회
- Keywords
- Cefotaxime; ESBL; Escherichia coli; Klebsiella pneumoniae; Susceptibility
- Citation
- 의료관련감염관리, v.28, no.1, pp 126 - 134
- Pages
- 9
- Journal Title
- 의료관련감염관리
- Volume
- 28
- Number
- 1
- Start Page
- 126
- End Page
- 134
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/73514
- DOI
- 10.14192/kjicp.2023.28.1.126
- ISSN
- 2508-5999
- Abstract
- Background: This study aimed to evaluate the trend of β-lactam resistance in Escherichia coli and Klebsiella pneumoniae bacteremia, the prevalence of cefotaxime-susceptible extendedspectrum β-lactamase-producing (ESBL) E. coli and K. pneumoniae, and the clinical characteristics of these infections.
Methods: A retrospective study was conducted in a tertiary hospital in Korea between 2011 and 2020. All patients with E. coli or K. pneumoniae bacteremia were identified, along with the results for the antibiotic susceptibility and ESBL production test for each isolate.
Results: Of 15 706 E. coli and K. pneumoniae bacteremia episodes, only 10 (0.06%) were caused by cefotaxime-susceptible ESBL-producing isolates, and their prevalence remained low during the study period. The proportion of ESBL-producing isolates gradually increased from 23.1% to 29.5%, whereas the proportion of carbapenem-resistant isolates rapidly increased from 0.9% to 12.1%. Furthermore, the proportion of carbapenem-resistant K. pneumoniae increased significantly and surpassed that of carbapenem-susceptible ESBL-producing K. pneumoniae in 2020. In a matched case-control study, the baseline characteristics of patients with cefotaxime-susceptible ESBL E. coli and K. pneumoniae bacteremia were similar to those with cefotaxime-resistant infections. There was no significant difference in 30-day mortality between patients with cefotaxime-susceptible and cefotaxime-resistant ESBL E. coli and K. pneumoniae bacteremia.
Conclusion: The prevalence of cefotaxime-susceptible ESBL E. coli and K. pneumoniae bacteremia and its mortality were very low, supporting the current guidelines for elective ESBL testing. The rapidly increasing carbapenem resistance is a concern.
- Files in This Item
-
- Appears in
Collections - ETC > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.